Beneficial role of adipose‐derived mesenchymal stem cells from microfragmented fat in a murine model of duchenne muscular dystrophy

2019 ◽  
Vol 60 (3) ◽  
pp. 328-335 ◽  
Author(s):  
Adrien Bouglé ◽  
Pierre Rocheteau ◽  
David Briand ◽  
David Hardy ◽  
Franck Verdonk ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Duchenne Muscular Dystrophy ◽  
Muscular Dystrophy ◽  
Murine Model ◽  
Beneficial Role

scholarly journals Human mesenchymal stem cells ectopically expressing full-length dystrophin can complement Duchenne muscular dystrophy myotubes by cell fusion

2005 ◽  
Vol 15 (2) ◽  
pp. 213-221 ◽  
Author(s):  
Manuel A.F.V. Gonçalves ◽  
Antoine A.F. de Vries ◽  
Maarten Holkers ◽  
Marloes J.M. van de Watering ◽  
Ietje van der Velde ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Duchenne Muscular Dystrophy ◽  
Muscular Dystrophy ◽  
Cell Fusion ◽  
Human Mesenchymal Stem Cells ◽  
Full Length

Mesenchymal Stem Cells for Regenerative Medicine for Duchenne Muscular Dystrophy

2020 ◽  
Author(s):  
Ahmed Elhussieny ◽  
Ken’ichiro Nogami ◽  
Fusako Sakai-Takemura ◽  
Yusuke Maruyama ◽  
AbdElraouf Omar Abdelbakey ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Duchenne Muscular Dystrophy ◽  
Muscular Dystrophy ◽  
Regenerative Medicine ◽  
Therapeutic Potential ◽  
Dystrophic Muscle ◽  
Multipotent Stem Cells ◽  
Pharmacological Target

Mesenchymal stem cells (MSCs) are multipotent stem cells that can be isolated from both foetal and adult tissues. Several groups demonstrated that transplantation of MSCs promoted the regeneration of skeletal muscle and ameliorated muscular dystrophy in animal models. Mesenchymal stem cells in skeletal muscle, also known as fibro-adipogenic progenitors (FAPs), are essential for the maintenance of skeletal muscle. Importantly, they contribute to fibrosis and fat accumulation in dystrophic muscle. Therefore, MSCs in muscle are a pharmacological target for the treatment of muscular dystrophies. In this chapter, we briefly update the knowledge on mesenchymal stem/progenitor cells and discuss their therapeutic potential as a regenerative medicine treatment of Duchenne muscular dystrophy.

14.1 T whole body MRI for detection of mesoangioblast stem cells in a murine model of duchenne muscular dystrophy

2011 ◽  
Vol 66 (6) ◽  
pp. 1704-1714 ◽  
Author(s):  
Boris Odintsov ◽  
Ju Lan Chun ◽  
James A. Mulligan ◽  
Suzanne E. Berry
Keyword(s):  
Stem Cells ◽  
Duchenne Muscular Dystrophy ◽  
Muscular Dystrophy ◽  
Murine Model ◽  
Whole Body ◽  
Whole Body Mri

Mesenchymal stem cells as anti-inflammatories: Implications for treatment of Duchenne muscular dystrophy

2010 ◽  
Vol 260 (2) ◽  
pp. 75-82 ◽  
Author(s):  
Thomas E. Ichim ◽  
Doru T. Alexandrescu ◽  
Fabio Solano ◽  
Fabian Lara ◽  
Rosalia De Necochea Campion ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Duchenne Muscular Dystrophy ◽  
Muscular Dystrophy

scholarly journals The Efficacy of Naïve versus Modified Mesenchymal Stem Cells in Improving Muscle Function in Duchenne Muscular Dystrophy: A Systematic Review

Biomedicines ◽  
2021 ◽  
Vol 9 (9) ◽  
pp. 1097
Author(s):  
Oscar Yuan-Jie Shen ◽  
Yi-Fan Chen ◽  
Hong-Tao Xu ◽  
Chien-Wei Lee
Keyword(s):  
Systematic Review ◽  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Duchenne Muscular Dystrophy ◽  
Muscular Dystrophy ◽  
Therapeutic Potential ◽  
In Vivo Model ◽  
Recessive Mutation ◽  
Culture Methods

As one of the most common genetic conditions, Duchenne muscular dystrophy (DMD) is a fatal disease caused by a recessive mutation resulting in muscle weakness in both voluntary and involuntary muscles and, eventually, in death because of cardiovascular failure. Currently, there is no pharmacologically curative treatment of DMD, but there is evidence supporting that mesenchymal stem cells (MSCs) are a novel solution for treating DMD. This systematic review focused on elucidating the therapeutic efficacy of MSCs on the DMD in vivo model. A key issue of previous studies was the material-choice, naïve MSCs or modified MSCs; modified MSCs are activated by culture methods or genetic modification. In summary, MSCs seem to improve pulmonary and cardiac functions and thereby improve survival regardless of them being naïve or modified. The improved function of distal skeletal muscles was observed only with primed MSCs treatment but not naïve MSCs. While MSCs can provide significant benefits to DMD mouse models, there is little to no data on the results in human patients. Due to the limited number of human studies, the differences in study design, and the insufficient understanding of mechanisms of action, more rigorous comparative trials are needed to elucidate which types of MSCs and modifications have optimal therapeutic potential.

scholarly journals Wharton’s Jelly-Derived Mesenchymal Stem Cells Reduce Fibrosis in a Mouse Model of Duchenne Muscular Dystrophy by Upregulating microRNA 499

Biomedicines ◽  
2021 ◽  
Vol 9 (9) ◽  
pp. 1089
Author(s):  
Sang Eon Park ◽  
Jang Bin Jeong ◽  
Shin Ji Oh ◽  
Sun Jeong Kim ◽  
Hyeongseop Kim ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Duchenne Muscular Dystrophy ◽  
Muscular Dystrophy ◽  
Wharton’S Jelly ◽  
Mdx Mice ◽  
Therapeutic Effects ◽  
Western Blots ◽  
Muscle Disorders ◽  
Wharton's Jelly

The aim of this study was to evaluate the therapeutic effects and mechanisms of Wharton’s jelly-derived mesenchymal stem cells (WJ-MSCs) in an animal model of Duchenne muscular dystrophy (DMD). Mdx mice (3–5 months old) were administered five different doses of WJ-MSCs through their tail veins. A week after injection, grip strength measurements, creatine kinase (CK) assays, immunohistochemistry, and western blots were performed for comparison between healthy mice, mdx control mice, and WJ-MSC-injected mdx mice. WJ-MSCs exerted dose-dependent multisystem therapeutic effects in mdx mice, by decreasing CK, recovering normal behavior, regenerating muscle, and reducing apoptosis and fibrosis in skeletal muscle. We also confirmed that miR-499-5p is significantly downregulated in mdx mice, and that intravenous injection of WJ-MSCs enhanced its expression, leading to anti-fibrotic effects via targeting TGFβR 1 and 3. Thus, WJ-MSCs may represent novel allogeneic “off-the-shelf” cellular products for the treatment of DMD and possibly other muscle disorders.

scholarly journals Mesenchymal Stem Cells: Emerging Therapy for Duchenne Muscular Dystrophy

PM&R ◽  
2009 ◽  
Vol 1 (6) ◽  
pp. 547-559 ◽  
Author(s):  
Chad D. Markert ◽  
Anthony Atala ◽  
Jennifer K. Cann ◽  
George Christ ◽  
Mark Furth ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Duchenne Muscular Dystrophy ◽  
Muscular Dystrophy ◽  
Emerging Therapy
Sign in / Sign up

Export Citation Format

Share Document